{"log_id": 6486337459082989362, "direction": 0, "words_result_num": 39, "words_result": [{"probability": {"variance": 7e-06, "average": 0.998166, "min": 0.993012}, "location": {"width": 115, "top": 254, "height": 32, "left": 186}, "words": "[注意事项"}, {"probability": {"variance": 0.002752, "average": 0.968377, "min": 0.877558}, "location": {"width": 80, "top": 289, "height": 28, "left": 185}, "words": "A.警告"}, {"probability": {"variance": 7.2e-05, "average": 0.996052, "min": 0.950201}, "location": {"width": 809, "top": 317, "height": 61, "left": 221}, "words": "雌激素替代治疗(ERT)和激素替代治疗(HRT)与某些癌症和心血管疾病的风险增"}, {"probability": {"variance": 0.006357, "average": 0.962104, "min": 0.783886}, "location": {"width": 127, "top": 319, "height": 27, "left": 186}, "words": "1.一般情况"}, {"probability": {"variance": 4.9e-05, "average": 0.996468, "min": 0.965764}, "location": {"width": 777, "top": 348, "height": 60, "left": 222}, "words": "加有关。如果在有完整子宫的妇女中仅使用非对抗的雌激素(即单纯使用雌激素)"}, {"probability": {"variance": 1e-06, "average": 0.999355, "min": 0.996406}, "location": {"width": 264, "top": 398, "height": 37, "left": 226}, "words": "与子宫内膜癌风险增加有关"}, {"probability": {"variance": 1.5e-05, "average": 0.99794, "min": 0.982652}, "location": {"width": 813, "top": 430, "height": 61, "left": 223}, "words": "激素替代治疗不应或继续用于预防心血管疾病或痴呆。必须经常认真权衡激素替代治"}, {"probability": {"variance": 0.000191, "average": 0.996343, "min": 0.915388}, "location": {"width": 814, "top": 460, "height": 60, "left": 223}, "words": "疗的利弊,包括考虑继续治疗时可能出现的风险。雌激素单独使用或与孕激素联合使"}, {"probability": {"variance": 4e-06, "average": 0.998984, "min": 0.990847}, "location": {"width": 768, "top": 492, "height": 57, "left": 225}, "words": "用,需在权衡妇女个体治疗目标和风险的情况下,使用最低有效剂量和最短疗程"}, {"probability": {"variance": 0.00325, "average": 0.97136, "min": 0.833385}, "location": {"width": 150, "top": 575, "height": 26, "left": 189}, "words": "2.心血管疾病"}, {"probability": {"variance": 0.000845, "average": 0.990938, "min": 0.839419}, "location": {"width": 685, "top": 580, "height": 53, "left": 232}, "words": "雌激素替代治疗(ERT)与中风和深静脉血栓风险(DVT)的增加有"}, {"probability": {"variance": 0.019889, "average": 0.873545, "min": 0.658632}, "location": {"width": 157, "top": 590, "height": 47, "left": 866}, "words": "制药有限"}, {"probability": {"variance": 0.000641, "average": 0.990325, "min": 0.870932}, "location": {"width": 819, "top": 628, "height": 61, "left": 231}, "words": "激素替代治疗(HRT)与心肌梗死(MI)和中风以及静脉血栓症及肺栓塞(PE)的风"}, {"probability": {"variance": 0.002273, "average": 0.988916, "min": 0.733545}, "location": {"width": 659, "top": 663, "height": 55, "left": 231}, "words": "险增加相关。如果发生或怀疑发生了这些情况,应该立即停用雌激素"}, {"probability": {"variance": 0.050881, "average": 0.733822, "min": 0.462812}, "location": {"width": 160, "top": 688, "height": 36, "left": 880}, "words": "西药商冬部"}, {"probability": {"variance": 0.00045, "average": 0.993286, "min": 0.90622}, "location": {"width": 792, "top": 712, "height": 60, "left": 232}, "words": "有可能发生动脉脉管性疾病的危险因素(如高血压,糖尿病,吸烟,高血脂和肥胖"}, {"probability": {"variance": 0.013665, "average": 0.96042, "min": 0.405838}, "location": {"width": 819, "top": 744, "height": 56, "left": 233}, "words": "和/或静脉血栓的危险因素(如有VTE的病史或家族史,肥胖和系统性红斑狼疮的患"}, {"probability": {"variance": 2e-06, "average": 0.998799, "min": 0.994037}, "location": {"width": 551, "top": 780, "height": 48, "left": 232}, "words": "者应进行适当地处理。应密切观察有血栓疾病风险的患者"}, {"probability": {"variance": 7.4e-05, "average": 0.996716, "min": 0.947901}, "location": {"width": 825, "top": 853, "height": 59, "left": 232}, "words": "在WHI的单用雌激素研究亚组中,报告单用雌激素妇女与安慰剂组相比,中风风险增"}, {"probability": {"variance": 0, "average": 0.999504, "min": 0.999295}, "location": {"width": 46, "top": 855, "height": 26, "left": 272}, "words": "中风"}, {"probability": {"variance": 0.001071, "average": 0.989398, "min": 0.812159}, "location": {"width": 819, "top": 883, "height": 58, "left": 232}, "words": "加有统计学显著性(45例对33例每10,000人年)。在第一年里就可观察到风险增加"}, {"probability": {"variance": 3e-06, "average": 0.998091, "min": 0.994579}, "location": {"width": 112, "top": 941, "height": 27, "left": 235}, "words": "并持续下去"}, {"probability": {"variance": 0.000365, "average": 0.99447, "min": 0.884048}, "location": {"width": 807, "top": 967, "height": 59, "left": 234}, "words": "在WHI的雌激素加孕激素亚组研究中,报告合并使用雌激素/孕激素妇女与安慰剂组"}, {"probability": {"variance": 0.006841, "average": 0.979201, "min": 0.470214}, "location": {"width": 809, "top": 997, "height": 57, "left": 235}, "words": "相比,中风风险增加有统计学显著性(31例对24例每10000人-年)。第一年后就可"}, {"probability": {"variance": 1.8e-05, "average": 0.997811, "min": 0.984407}, "location": {"width": 267, "top": 1045, "height": 39, "left": 234}, "words": "观察到风险增加并持续下去"}, {"probability": {"variance": 0.000146, "average": 0.994498, "min": 0.943644}, "location": {"width": 814, "top": 1107, "height": 60, "left": 236}, "words": "在WH单用雌激素亚组研究中,单用雌激素妇女与安慰剂组相比,未报告总体上对冠"}, {"probability": {"variance": 0.036536, "average": 0.894793, "min": 0.513554}, "location": {"width": 107, "top": 1110, "height": 26, "left": 236}, "words": "b.冠心病"}, {"probability": {"variance": 0.000196, "average": 0.994733, "min": 0.915634}, "location": {"width": 819, "top": 1136, "height": 61, "left": 237}, "words": "心病(CHD)事件(定义为非致死性心肌梗塞、无症状心肌梗塞或因CHD死亡)的影"}, {"probability": {"variance": 0, "average": 0.965916, "min": 0.965916}, "location": {"width": 26, "top": 1199, "height": 23, "left": 238}, "words": "响"}, {"probability": {"variance": 0.007785, "average": 0.965894, "min": 0.558938}, "location": {"width": 830, "top": 1224, "height": 56, "left": 238}, "words": "在WHI的雌激素加孕激素亚组研究中,每天服用倍美安(0.625mg结合雌激素加2.5mg"}, {"probability": {"variance": 5.1e-05, "average": 0.996471, "min": 0.967004}, "location": {"width": 818, "top": 1251, "height": 56, "left": 238}, "words": "醋酸甲羟孕酮)组相对于安慰剂组,未报告冠心病(CHD)事件的风险有统计学意义"}, {"probability": {"variance": 0.01153, "average": 0.962576, "min": 0.479953}, "location": {"width": 811, "top": 1278, "height": 58, "left": 239}, "words": "的显著增加(每10000人-年发生CHD事件的风险是39对33)。在第一年显示相对风险"}, {"probability": {"variance": 2e-06, "average": 0.998673, "min": 0.994321}, "location": {"width": 416, "top": 1321, "height": 44, "left": 241}, "words": "增加,第2至5年报道相对风险有降低的趋势"}, {"probability": {"variance": 0.012619, "average": 0.958695, "min": 0.383196}, "location": {"width": 813, "top": 1360, "height": 59, "left": 242}, "words": "在确诊为心脏病的绝经后妇女(n=2,763:平均年龄66.7岁)中进行的一项级预防心"}, {"probability": {"variance": 0.000134, "average": 0.995445, "min": 0.930927}, "location": {"width": 825, "top": 1389, "height": 59, "left": 243}, "words": "血管疾病的对照临床试验(HES研究),并未证明结合雌激素加醋酸甲羟孕酮联合用"}, {"probability": {"variance": 0.000523, "average": 0.989104, "min": 0.891994}, "location": {"width": 816, "top": 1419, "height": 57, "left": 243}, "words": "药对心血管有益。平均随访4.1年,对已明确有冠状动脉性心脏病的绝经后妇女,使用"}, {"probability": {"variance": 0.010879, "average": 0.957861, "min": 0.479559}, "location": {"width": 810, "top": 1444, "height": 65, "left": 243}, "words": "倍美安进行的治疗没有降低CHD事件的总发生率。在第一年,倍美安治疗组相对于"}, {"probability": {"variance": 0.012803, "average": 0.946, "min": 0.463044}, "location": {"width": 803, "top": 1475, "height": 61, "left": 245}, "words": "安慰剂组发生CHD的事件增加,但随后几年并未出现此现象。参加PERS研究的大群"}, {"probability": {"variance": 0.04551, "average": 0.842081, "min": 0.374737}, "location": {"width": 820, "top": 1504, "height": 60, "left": 246}, "words": "中有2321名妇女同意参加一个开放的:HERS扩展研究( HERC T研究研究"}], "language": 3}